^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DIRAS3 expression

    i
    Other names: DIRAS3, DIRAS Family GTPase 3, Distinct Subgroup Of The Ras Family Member 3, Rho-Related GTP-Binding Protein RhoI, DIRAS Family, GTP-Binding RAS-Like 3, Ras Homolog Gene Family, Member I, GTP-Binding Protein Di-Ras3, NOEY2, ARHI, RHOI
    Entrez ID:
    9077
    Related biomarkers:
    Expression
    1year
    Differential effects of the LncRNA RNF157-AS1 on epithelial ovarian cancer cells through suppression of DIRAS3- and ULK1-mediated autophagy. (PubMed, Cell Death Dis)
    Therefore, the OS and PPS times were longer in EOC patients with elevated RNF157-AS1 expression. RNF157-AS1-mediated autophagy has potential clinical significance in DDP chemotherapy for EOC patients.
    Journal
    |
    DIRAS3 (DIRAS Family GTPase 3) • TRIM38 (Tripartite Motif Containing 38)
    |
    DIRAS3 expression
    over1year
    DIRAS3, GPR171 and RAC2 were identified as the key molecular patterns associated with brain metastasis of breast cancer. (PubMed, Front Oncol)
    Their correlation analysis with immune cells showed that the correlation coefficient between the expression levels of DIRAS3 and immune cells was low, and the expression levels of GPR171 and RAC2 were more closely correlated with B cells and macrophages. The expression of DIRAS3, GPR171 and RAC2, genes associated with brain metastasis, was reduced in metastatic breast cancer, and GPR171 was found to promote brain metastasis of breast cancer cells by inducing B cells and thereby.
    Journal
    |
    DIRAS3 (DIRAS Family GTPase 3) • RAC2 (Rac Family Small GTPase 2)
    |
    DIRAS3 expression
    almost2years
    Resveratrol Contrasts IL-6 Pro-Growth Effects and Promotes Autophagy-Mediated Cancer Cell Dormancy in 3D Ovarian Cancer: Role of miR-1305 and of Its Target ARH-I. (PubMed, Cancers (Basel))
    Clinically relevant, bioinformatic analysis of a transcriptomic database showed that the high expression of DIRAS3 and MAP1LC3B mRNAs together with that of CDKN1A, directing a cellular dormant phenotype, predicts better overall survival in ovarian cancer patients, and this correlates with MIR1305 downregulation. The possibility of maintaining a permanent cell dormancy in ovarian cancer by the chronic administration of RV should be considered as a therapeutic option to prevent the "awakening" of cancer cells in response to a permissive microenvironment, thus limiting the risk of tumor relapse and metastasis.
    Journal
    |
    IL6 (Interleukin 6) • DIRAS3 (DIRAS Family GTPase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MAP1LC3B (Microtubule Associated Protein 1 Light Chain 3 Beta) • BECN1 (Beclin 1)
    |
    DIRAS3 expression
    2years
    GTP-binding protein Di-RAS3 diminishes the migration and invasion of non-small cell lung cancer by inhibiting the RAS/extracellular-regulated kinase pathway. (PubMed, Bioengineered)
    Mechanistically, DIRAS3 may inhibit the migration and invasion of NSCLC cells by inhibiting the RAS/extracellular-regulated kinase (ERK) signaling pathway. Collectively, our findings indicate that DIRAS3 could serve as a potential therapeutic target biomarker for NSCLC.
    Journal
    |
    DIRAS3 (DIRAS Family GTPase 3)
    |
    DIRAS3 expression • DIRAS3 overexpression
    over2years
    DIRAS3: An Imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy and tumor dormancy. (PubMed, Mol Cancer Ther)
    DIRAS3-mediated induction of autophagy facilitates the survival of dormant cancer cells in a nutrient-poor environment. DIRAS3 expression in dormant, drug-resistant autophagic cancer cells can serve as a biomarker and as a target for novel therapy to eliminate the residual disease that remains after conventional therapy.
    Review • Journal
    |
    DIRAS3 (DIRAS Family GTPase 3)
    |
    DIRAS3 expression
    over3years
    Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma. (PubMed, Mil Med Res)
    The concurrent re-expression of DIRAS3 and p53 is a more effective approach to HNSCC treatment than current treatment strategies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • DIRAS3 (DIRAS Family GTPase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    MYC expression • CCND1 expression • TP53 expression • DIRAS3 expression
    over3years
    DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. (PubMed, Cell Rep)
    Disruption of K-RAS cluster formation requires the N terminus of DIRAS3 and interaction of both DIRAS3 and K-RAS with the plasma membrane. Interaction of DIRAS3 with both K-RAS and H-RAS suggests a strategy for inhibiting oncogenic RAS function.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • DIRAS3 (DIRAS Family GTPase 3)
    |
    DIRAS3 expression